The Week That Was
GOOOOOOOOOOOOOD MORNING READERS!
We hope you had a restful weekend, because you’re in for a helping heap of The Week That Was. Last week was the equivalent of editorial catnip for our team:
It’s too late to go back to bed, so please read on for this Monday edition of The Week That Was.
► MEDICARE FOR ALL? WE WOULDN’T BET THE HOUSE ON IT
Last week, a group of 17 Democratic senators, led by Senator Bernie Sanders, rolled out “Medicare for All” legislation, which seeks to replace the current U.S. insurance model with a single government-run plan that would cover all Americans. As proposed, the benefits would be more expansive than what is offered by most single-payer countries. Opponents of the proposal, including some Democrats, have called for the nonpartisan Congressional Budget Office (CBO) to “score” the bill to provide a cost estimate. Critics also argue the bill does not include the tax increases needed to fund the program. Republican leaders and President Trump all said the bill is unlikely to pass.
► OUR TAKE
Senator Sanders’s bill may have as good a chance of becoming law as the grass has of beating the lawnmower, BUT, that’s not necessarily the point. With more than a third of the Democratic caucus backing the bill, and presumably a few of those are presidential hopefuls, the “Medicare for All” bill signals the continuance of a long-term national debate. Drug prices will surely be at the center of arguments for single-payer advocates. Our advice to pricing teams: remember these two points:
► GOTTLIEB SAYS BUCK STOPS HERE; PLEDGES TO CLOSE LOOPHOLE IN ORPHAN DRUG LAW
This week, FDA Commissioner Scott Gottlieb announced that the FDA will release new guidance intended to close a “loophole” that grants orphan designation for pediatric populations suffering from a non-orphan adult disease. This designation has caused “unintended conflict” with the Pediatric Research Equity Act and resulted in allowing pharmaceutical sponsors to bypass clinical trial study for pediatric sub-populations. Commissioner Gottlieb said in practice the loophole contravenes Congress’s intention with the Orphan Drug Act – which is to encourage more pediatric study; not less. Meanwhile, pharmaceutical research was attacked from a different angle, as a new Journal of the American Medical Association (JAMA) study of 10 cancer treatments suggested that the research investment per drug is much lower than the industry’s regularly cited figure of ~$2.7 billion.
► OUR TAKE
R&D cost is a real factor developers must consider when balancing the needs of a business …BUT, in the fight for hearts and minds, messaging about R&D is no panacea. Why? R&D costs are all about us and not about patients. Our advice: don’t focus on research costs to defend drug prices. Instead, companies should get specific about the actions they take to help patients, families and physicians – therapy and beyond. This can include physician education, community support programs, better patient resources…the list goes on!
► EQUIFAX’S CRISIS RESPONSE STRATEGY
Last week, credit reporting company Equifax revealed a cybersecurity breach that jeopardized 143 million U.S. consumers’ personally identifiable information. And that was just the tip of the iceberg. Word got around soon after that three Equifax officials, including the CFO, sold nearly $2 million of the company’s shares days after the breach was actually discovered back in July. Equifax then launched a cybersecurity response protocol, including “Cybersecurity Incident & Important Consumer Information,” social media responses and a video statement. The irony? You have to enter the last 6 digits of your Social Security Number to determine if your information was jeopardized and enroll in their complimentary credit file protection product “TrustedID Premier.” No thank you?!
► OUR TAKE
Cybersecurity breaches make consumers feel vulnerable, and as our past newsletters have reported, they are an acute, continued risk for healthcare companies. Breached information could mean exposing a patient’s sensitive disease status or treatment information. As we forge into this brave new world, healthcare companies should proactively communicate their efforts to protect patient information. Should disaster strike, communicate updates consistently across all channels and use sensitive and genuine language. Avoid robotic, teleprompter-like delivery that EQUIFAX used at all costs!
Until next week.
– The Reputation & Risk Management Practice
Our mailing address is: